摘要
化学治疗晚期非小细胞肺癌疗效似已达到平台,靶向药物是进一步提高疗效的关键。尽管第一代靶向治疗药物开发的种类繁多,但仅有少数药物在前瞻性、随机的Ⅲ期临床试验中显示出生存优势。第二代靶向治疗药物——多靶点抑制剂,可同时阻断肿瘤多个的信号传导,临床试验的初步结果表明,毒副作用可以耐受,效果较好,治疗晚期非小细胞肺癌已显示出较好的应用前景。
The results of chemotherapy in the treatment of advanced non - small cell lung cancer （NSCLC） had reached a plateau. Targeted therapy is the key to improving efficacy. However, in the last few years, only several targeted drugs that target angiogenesis （bevacuzumab） and the epidermal growth factor receptor （erlotinib） axis have showed survival benefits in prospective, randomized, phase Ⅲ clinical trials. Recent data suggest that muhitargeted inhibitors might have greater activity owing to their ability to simultaneously block key signaling pathways. Preliminary results of such agents in clinical trials shows that they have a well - tolerated toxicity profile, and might have a promising value in the treatment of advanced non - small cell lung cancer.
出处
《癌症进展》
2007年第2期151-157,215,共8页
Oncology Progress
